IMMUTEP LTD-SP ADR (IMMP)
US45257L1089 - ADR
Wednesday's pre-market session: top gainers and losers
Stay updated with the stocks that are on the move in Wednesday's pre-market session.
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Media Release SYDNEY, AUSTRALIA, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (
Immutep receives A$2.6M R&D tax incentive from French Government (NASDAQ:IMMP)
Immutep receives €1.60M research and development tax incentive payment from the French Government to support global clinical development and preclinical...
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
Media Release SYDNEY, AUSTRALIA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (
Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
SYDNEY, AUSTRALIA, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
Media Release A total of 171 head and neck squamous cell carcinoma (HNSCC) patients enrolled in randomised, multicentre Phase IIb trial evaluating efti in...
Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer
Media Release Statistically significant increases of Th1 biomarkers (IFN-gamma, CXCL-10), circulating immune cells (lymphocytes), and RNA levels of...
Immutep receives ~A$1.13 million R&D Tax Incentive
Media Release (Code: ASX: IMM; NASDAQ: IMMP) SYDNEY, AUSTRALIA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”...
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use
Comparability of Drug Substance and Drug Product manufactured at 2,000L scale achieved...
Immutep to Participate in September Investor Conferences
SYDNEY, AUSTRALIA, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage...
7 Stocks That Could Triple Your Money by 2024
If you want to get well ahead of the market and don’t mind the risk factor, check out these stocks to triple your money.
First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma
Media Release SYDNEY, AUSTRALIA, July 28, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a...
Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor
Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company...
3 Best Penny Stocks Under $3 to Buy in June
If you don’t mind the immense risks associated with high-potential opportunities, these best penny stocks under $3 could be for you.
Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting
Media Release Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression levels, and median Duration of Response not reached...
Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer
Sydney, Australia, June 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited, an Australian company (ASX: IMM) (Nasdaq: IMMP) (Immutep or the Company), is...
Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study
Media Release Appointment of Charles River Laboratories ("Charles River") to run Immutep’s preclinical toxicology study evaluating the safety and...
Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting
Media Release New data published from Part C of TACTI-002 Phase II Trial evaluating eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and...
Immutep stock rises as efti combo shows promise in phase 1 lung cancer trial
Immutep (IMMP) said eftilagimod alpha plus anti-PD-1 therapy and doublet chemotherapy showed promise in a phase 1 lung cancer trial. Read more here
Immutep surges 106% on mid-stage data for lung cancer drug
Immutep (IMMP) said Wednesday that lung cancer patients on its lead asset efti, and Merck's (MRK) Keytruda posted a median overall survival of 25 months. Read more here.
Immutep stock jumps on mid-stage data for lung cancer drug
Immutep (IMMP) said Wednesday that lung cancer patients on its lead asset efti, and Merck's (MRK) Keytruda posted a median overall survival of 25 months. Read more here.
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
Media Release Immuno-oncology combination of eftilagimod alpha (efti) and the leading anti-PD-1 therapy generates meaningful long-term survival in...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off Wednesday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning!
Immutep's eftilagimod alpha receives positive FDA feedback for late-stage (NASDAQ:IMMP)
Immutep (IMMP) announced that it received positive feedback from the US Food and Drug Administration regarding the its late-stage clinical development plans for eftilagimod alpha,...
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer
Media Release SYDNEY, AUSTRALIA, May 16, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a...